ALMERE, the Netherlands, April 17, 2015 /CNW/ - Emotional Brain, an innovative Dutch company that is developing two drugs for sexual dysfunction in women, is pleased to announce that the core patent protecting one of these drugs - Lybridos - has been extended in the U.S. for three years, well into 2030. The corresponding patent applications in Europe, Japan, and Mexico have also received notices of intention to grant, and the patents are expected within the next few months. This patent term extension in the U.S. and the pending new patents will add to the protection that Lybridos already has in other countries, including China, Australia, Canada, and Hong Kong.
Lybrido, the other drug being developed by Emotional Brain for sexual dysfunction in women, also has excellent patent protection (mid- to late-2020s) in numerous countries, including the U.S., Europe, China, Australia, Mexico and Hong Kong.
Patent protection on the intellectual property for both Lybrido and Lybridos allows for market exclusivity until these patents expire. The patent extension and new intentions to grant for Lybridos give Emotional Brain a stronger market position and enhanced company valuation.
Adriaan Tuiten, CEO, says: "Sexual dysfunction is an under-appreciated problem that affects millions of women. We are working very hard to develop Lybrido and Lybridos and ultimately obtain marketing approval, with the full conviction that these drugs will be able to help many women afflicted by sexual desire problems."
About Lybrido and Lybridos
In 2004, Emotional Brain began a scientific quest that has led to the development of two effective drugs for the treatment of Female Sexual Dysfunction (FSD): Lybrido and Lybridos. Both drugs are aimed at treating the most common complaint among these women: Low sexual desire and decreased sexual arousal. The two drugs have different mechanisms of action to address the individual causes of sexual complaints. Lybrido is designed for women with FSD (with low sexual desire/arousal) due to a relatively insensitive brain system for sexual signals. Lybridos is designed for a different group of women with FSD, those for whom an overactive sexual inhibition system in the brain is the cause of their condition. Both Lybrido and Lybridos are "on demand" drugs, to be taken only when desired. Emotional Brain anticipates initiating Phase 3 studies in the United States and Europe in the course of 2015.
SOURCE Emotional Brain